We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

14 hedge funds and large institutions have $20.1M invested in Aurinia Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

2% more capital invested

Capital invested by funds: $19.7M → $20.1M (+$420K)

18% less funds holding

Funds holding: 17 → 14 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
5
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$1.16M
2
Renaissance Technologies
Renaissance Technologies
New York
+$29.2K
3
RG
Redmile Group
California
+$23.8K
4
LOAMU
Lombard Odier Asset Management (USA)
New York
+$7.69K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.91K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$260K
2
Goldman Sachs
Goldman Sachs
New York
-$61K
3
UBS Group
UBS Group
Switzerland
-$6K
4
Bank of America
Bank of America
North Carolina
-$3K
5
Morgan Stanley
Morgan Stanley
New York
-$153
Name Holding Trade Value Shares
Change 		Change in
Stake
GPP
1
Great Point Partners
Connecticut
$7.19M – – –
NMC
2
NEA Management Company
Maryland
$7.05M – – –
BBA
3
Baker Bros. Advisors
New York
$2.12M – – –
EAM
4
EverPoint Asset Management
Connecticut
$1.66M – – –
A
5
Abingworth
United Kingdom
$1.39M +$1.16M +423,729 +480%
LOAMU
6
Lombard Odier Asset Management (USA)
New York
$283K +$7.69K +2,813 +3%
Millennium Management
7
Millennium Management
New York
$139K -$260K -95,200 -66%
Renaissance Technologies
8
Renaissance Technologies
New York
$114K +$29.2K +10,700 +35%
RG
9
Redmile Group
California
$79K +$23.8K +8,700 +44%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$30K -$150 -55 -0.5%
Bank of Montreal
11
Bank of Montreal
Ontario, Canada
$21K – – –
Morgan Stanley
12
Morgan Stanley
New York
$6K -$153 -56 -3%
TRCT
13
Tower Research Capital (TRC)
New York
$4K +$1.91K +700 +233%
Goldman Sachs
14
Goldman Sachs
New York
– -$61K -21,118 Closed
UBS Group
15
UBS Group
Switzerland
– -$6K -2,019 Closed
Bank of America
16
Bank of America
North Carolina
– -$3K -1,000 Closed
Toronto Dominion Bank
17
Toronto Dominion Bank
Ontario, Canada
– -$63 -23 -64%

AUPH Hedge Fund Activity: Q2 2016 in Review

14 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2016, worth a combined $20.1M — up 2.1% from $19.7M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of AUPH and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Abingworth, adding an estimated $1.16M. The largest seller was Millennium Management, cutting an estimated $260K.

  • 14 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2016, down from 17 in Q1 2016.
  • Funds reported $20.1M of Aurinia Pharmaceuticals stock for Q2 2016, up 2.1% quarter-over-quarter.
  • 0 funds opened new Aurinia Pharmaceuticals positions in Q2 2016 and 3 closed out, a net change of -3 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q2 2016 was Abingworth, an estimated $1.16M added.
  • The largest Aurinia Pharmaceuticals seller in Q2 2016 was Millennium Management, an estimated $260K sold.

Based on aggregated 13F filings for Q2 2016.